VISX gets review of Nidek's ITC (International Trade Commission) victory:
This article was originally published in Clinica
VISX, the laser refractive surgery manufacturer and licensor fighting to keep exclusivity on its US patents, has won a review of portions of the unfavourable decision handed down by the International Trade Commission (ITC) in December. The administrative law judge made a ruling that Japanese rival manufacturer Nidek did not infringe VISX's '418 patent. The case is due to be heard on March 6, though further appeals are likely, whatever the outcome.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.